Subscribe to our Newsletters !!


    Rundown of WHO’s main 8 contenders for COVID-19 antibody

    Five months into the worldwide flare-up of COVID-19, the world is attempting to beat the clock to set up an antibody for treating coronavirus patients. World Health Organisation(WHO) has recognized top eight contender for the coronavirus antibody: CanSino Biological Inc/Beijing Institute of Biotechnology: The Chinese antibody has been named as a top contender by WHO.

    First COVID-19 antibody human preliminary discovers it is protected, instigates safe reaction

    The first COVID-19 antibody to arrive at stage I clinical preliminary is sheltered, very much endured, and equipped for creating an insusceptible reaction against the novel coronavirus in people, says another exploration distributed in The Lancet diary. As indicated by the investigation of 108 grown-ups, the immunization delivered killing antibodies, and a reaction interceded by

    US Trial Shows Gilead’s Remdesivir Drug Works Best in Coronavirus Patients Who Require Extra Oxygen

    The US National Institutes of Health (NIH) on Friday said that information from its preliminary of Gilead Sciences Inc’s remdesivir show that the medication offers the most advantage for COVID-19 patients who need additional oxygen yet don’t require mechanical ventilation. The companion investigated information was distributed in the New England Journal of Medicine. The preliminary,

    CanSino Biologics Inc New Corona immunization seems protected, compelling in early trials

    A coronavirus immunization developed by CanSino Biologics Inc gives off an impression of being sheltered and prompted a quick invulnerable reaction in its first human trial, Chinese analysts gave an account of Friday in The Lancet clinical diary. CanSino utilizes a debilitated regular cold infection called an adenovirus – and Friday’s investigation indicated individuals whose

    Novavax begins Phase 1 clinical preliminary of coronavirus immunization competitor

    Novavax Inc said on Monday it has begun the Phase 1 clinical preliminary of a novel coronavirus antibody applicant and has selected the preliminary’s first members, with primer outcomes scheduled for July. The Maryland-based late-stage biotechnology organization in April said it distinguished the up-and-comer, NVX-CoV2373, with which it intended to utilize its Matrix-M adjuvant to

    Covid may never leave even with an antibody : Report

    Considerably after a COVID-19 antibody is created and conveyed, the coronavirus will probably stay for quite a long time to come, and may in the long run, become endemic like HIV, measles and chickenpox, The Washington Post detailed. As per the US every day, specialists in the study of disease transmission state grasping the delayed

    GSK to deliver 1 billion dosages of coronavirus antibody promoter in 2021

    GlaxoSmithKline Plc will grow creation of antibody adequacy boosters, or adjuvants, to deliver 1 billion portions in 2021 for use in shots for COVID-19, the British drugmaker said on Thursday. The London-recorded organization said it was in converses with governments on sponsorship for the program, which would adequately take into account a scaling up of

    Handling airborne transmission of COVID-19 inside

    Forestalling airborne transmission of Covid-19 ought to be the following front of the fight against the infection, contend specialists from the University of Surrey. In an investigation distributed by the City and Environment Interaction diary, researchers from Surrey’s Global Center for Clean Air Research (GCARE), along with accomplices from Australia’s Queensland University and Technology, contend